Biomark Diagnostics Inc. (CSE:BUX)
Canada
· Delayed Price · Currency is CAD 0.2500
0.00 (0.00%)
Apr 25, 2025, 9:40 AM EDT
Biomark Diagnostics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 0.16 | 0.16 | 0.15 | 0.04 | - | 0.26 | Upgrade
|
| Revenue Growth (YoY) | -4.98% | 6.34% | 249.38% | - | - | - | Upgrade
|
| Gross Profit | 0.16 | 0.16 | 0.15 | 0.04 | - | 0.26 | Upgrade
|
| Selling, General & Admin | 0.71 | 0.75 | 0.73 | 0.65 | 0.9 | 0.54 | Upgrade
|
| Research & Development | 0.76 | 0.65 | 0.55 | 0.5 | 0.12 | 0.04 | Upgrade
|
| Operating Expenses | 2.07 | 1.87 | 1.99 | 1.33 | 1.03 | 1.45 | Upgrade
|
| Operating Income | -1.92 | -1.71 | -1.84 | -1.28 | -1.03 | -1.18 | Upgrade
|
| Interest Expense | -0.07 | -0.09 | -0.11 | -0.04 | - | -0 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | - | 0 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | - | -0 | -0.01 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | 0.36 | 0.11 | -0.13 | -0.06 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -1.9 | -1.43 | -1.84 | -1.45 | -1.1 | -1.2 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0 | -0.02 | Upgrade
|
| Pretax Income | -1.9 | -1.43 | -1.84 | -1.45 | -1.09 | -1.22 | Upgrade
|
| Net Income | -1.9 | -1.43 | -1.84 | -1.45 | -1.09 | -1.22 | Upgrade
|
| Net Income to Common | -1.9 | -1.43 | -1.84 | -1.45 | -1.09 | -1.22 | Upgrade
|
| Shares Outstanding (Basic) | 685 | 85 | 83 | 78 | 73 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 685 | 85 | 83 | 78 | 73 | 71 | Upgrade
|
| Shares Change (YoY) | 709.75% | 2.97% | 6.22% | 6.31% | 2.82% | 8.16% | Upgrade
|
| EPS (Basic) | -0.00 | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 | Upgrade
|
| Free Cash Flow | -0.86 | -0.99 | -0.92 | -1.26 | -0.81 | -0.45 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | -1235.35% | -1046.96% | -1198.95% | -2922.50% | - | -449.31% | Upgrade
|
| Profit Margin | -1223.42% | -874.52% | -1200.21% | -3309.36% | - | -461.59% | Upgrade
|
| Free Cash Flow Margin | -554.34% | -604.65% | -599.20% | -2875.13% | - | -172.66% | Upgrade
|
| EBITDA | -1.9 | -1.7 | -1.83 | -1.28 | -1.03 | -1.17 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | Upgrade
|
| EBIT | -1.92 | -1.71 | -1.84 | -1.28 | -1.03 | -1.18 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.